MPM Bioimpact LLC Acquires 58,895 Shares of Janux Therapeutics, Inc. (NASDAQ:JANX)

MPM Bioimpact LLC lifted its position in shares of Janux Therapeutics, Inc. (NASDAQ:JANX - Free Report) by 34.4% during the fourth quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The firm owned 230,000 shares of the company's stock after purchasing an additional 58,895 shares during the period. Janux Therapeutics accounts for approximately 1.7% of MPM Bioimpact LLC's investment portfolio, making the stock its 28th biggest holding. MPM Bioimpact LLC owned approximately 0.44% of Janux Therapeutics worth $12,314,000 at the end of the most recent reporting period.

Other large investors also recently made changes to their positions in the company. Lester Murray Antman dba SimplyRich increased its stake in shares of Janux Therapeutics by 205.3% during the fourth quarter. Lester Murray Antman dba SimplyRich now owns 24,315 shares of the company's stock worth $1,301,000 after purchasing an additional 16,351 shares during the period. abrdn plc bought a new position in shares of Janux Therapeutics during the fourth quarter worth approximately $3,430,000. Barclays PLC increased its stake in shares of Janux Therapeutics by 496.5% during the third quarter. Barclays PLC now owns 174,061 shares of the company's stock worth $7,907,000 after purchasing an additional 144,883 shares during the period. Legal & General Group Plc increased its stake in Janux Therapeutics by 45.3% during the 4th quarter. Legal & General Group Plc now owns 34,540 shares of the company's stock worth $1,849,000 after acquiring an additional 10,776 shares during the period. Finally, Rhumbline Advisers increased its stake in Janux Therapeutics by 1.6% during the 4th quarter. Rhumbline Advisers now owns 38,153 shares of the company's stock worth $2,043,000 after acquiring an additional 599 shares during the period. Institutional investors own 75.39% of the company's stock.

Insider Activity at Janux Therapeutics

In related news, Director Ra Capital Management, L.P. bought 341,742 shares of the business's stock in a transaction on Wednesday, March 5th. The shares were purchased at an average cost of $30.64 per share, with a total value of $10,470,974.88. Following the acquisition, the director now owns 9,658,988 shares of the company's stock, valued at $295,951,392.32. This represents a 3.67% increase in their ownership of the stock. The purchase was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, insider Andrew Hollman Meyer sold 3,333 shares of Janux Therapeutics stock in a transaction dated Thursday, May 1st. The stock was sold at an average price of $32.03, for a total value of $106,755.99. Following the transaction, the insider now directly owns 82,139 shares in the company, valued at $2,630,912.17. The trade was a 3.90% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold a total of 10,001 shares of company stock valued at $313,964 in the last 90 days. 8.10% of the stock is owned by corporate insiders.

Janux Therapeutics Price Performance

Shares of NASDAQ JANX traded up $1.01 during mid-day trading on Friday, hitting $24.28. 931,458 shares of the stock traded hands, compared to its average volume of 867,970. Janux Therapeutics, Inc. has a twelve month low of $22.48 and a twelve month high of $71.71. The company has a market cap of $1.44 billion, a PE ratio of -20.75 and a beta of 3.24. The firm has a 50 day simple moving average of $28.66 and a two-hundred day simple moving average of $40.74.

Janux Therapeutics (NASDAQ:JANX - Get Free Report) last released its quarterly earnings data on Thursday, May 8th. The company reported ($0.38) earnings per share for the quarter, beating the consensus estimate of ($0.43) by $0.05. Janux Therapeutics had a negative return on equity of 10.47% and a negative net margin of 463.91%. On average, equities research analysts anticipate that Janux Therapeutics, Inc. will post -1.38 earnings per share for the current fiscal year.

Analysts Set New Price Targets

A number of equities analysts have commented on JANX shares. Wedbush restated an "outperform" rating and set a $76.00 price objective (up previously from $75.00) on shares of Janux Therapeutics in a research note on Friday, February 28th. Scotiabank lowered their price objective on Janux Therapeutics from $62.00 to $41.00 and set a "sector perform" rating on the stock in a research note on Friday, February 28th. Finally, HC Wainwright restated a "buy" rating and set a $70.00 price objective on shares of Janux Therapeutics in a research note on Monday, March 3rd. One equities research analyst has rated the stock with a hold rating, eight have issued a buy rating and two have issued a strong buy rating to the stock. Based on data from MarketBeat.com, the stock presently has an average rating of "Buy" and a consensus price target of $95.25.

Janux Therapeutics Company Profile

Janux Therapeutics, Inc, a clinical stage biopharmaceutical company, develops immunotherapies based on Tumor Activated T Cell Engagers (TRACTr) and Tumor Activated Immunomodulators (TRACIr) platforms technology to treat patients suffering from cancer. The company's clinical candidates comprise JANX007, a prostate-specific membrane antigen or PSMA-TRACTr, which is in Phase 1 clinical trial in adults for the treatment of metastatic castration-resistant prostate cancer (mCRPC) and the vasculature of other tumors; and JANX008, an epidermal growth factor receptor or EGFR-TRACTr that is in Phase 1 clinical trial for the treatment of multiple solid cancers, including colorectal cancer, squamous cell carcinoma of the head and neck, non-small cell lung cancer, and renal cell carcinoma.